Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 9/20 | 0.54 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 7/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405906 | 0.96 | TASP1 (0.55) | ENPEPTASP1FOLH1BACE1BACE2 | |
| SCHEMBL30355008 | 0.91 | ENPEP (0.58) | ENPEPTASP1BACE1BACE2 | |
| SCHEMBL30163434 | 0.90 | BACE1 (0.52) | ENPEPTASP1FOLH1BACE1BACE2 | |
| SCHEMBL31491410 | 0.90 | ENPEP (0.57) | ENPEPTASP1BACE1 | |
| SCHEMBL30059944 | 0.90 | ENPEP (0.60) | ENPEPFOLH1BACE1 | |
| SCHEMBL29815897 | 0.89 | FOLH1 (0.60) | FOLH1BACE1BACE2 | |
| SCHEMBL29624626 | 0.89 | BACE1 (0.59) | ENPEPTASP1FOLH1BACE1BACE2 | |
| SCHEMBL31720926 | 0.89 | ENPEP (0.55) | ENPEPTASP1FOLH1BACE1BACE2 | |
| SCHEMBL31287158 | 0.89 | ENPEP (0.54) | ENPEPTASP1FOLH1BACE1 | |
| SCHEMBL30400303 | 0.88 | ENPEP (0.53) | ENPEPTASP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | disclosed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | ENPEP 214/4885TASP1 2699/4885FOLH1 913/4885 |
| US-11814417-B2 | GIP agonist compounds and methods | GIPR, GLP1R, GPR119 | ENPEP 214/4885TASP1 2699/4885FOLH1 913/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | ENPEP 214/4885TASP1 2699/4885FOLH1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.